Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL-Reference-Cited by-同舟云学术

Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL

Published:2024-03-07 Issue:10 Volume:143 Page:933-937
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

O’Connor David¹²^ORCID,Valle-Inclán Jose Espejo³^ORCID,Conde Lucia¹^ORCID,Bloye Gianna¹^ORCID,Rahman Sunniyat¹⁴⁵,Costa Joana R.¹^ORCID,Bartram Jack²^ORCID,Adams Stuart⁶^ORCID,Wright Gary⁶,Elrick Hillary³^ORCID,Wall Kerry⁷,Dyer Sara⁷,Howell Christopher⁸,Jigoulina Galina⁹,Herrero Javier¹^ORCID,Cortes-Ciriano Isidro³,Moorman Anthony V.¹⁰^ORCID,Mansour Marc R.¹¹¹^ORCID

Affiliation:

1. 1UCL Cancer Institute, University College London, London, United Kingdom

2. 2Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom

3. 3European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United Kingdom

4. 4Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

5. 5Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia

6. 6Specialist Integrated Haematology and Malignancy Diagnostic Service-Haematology, Great Ormond Street Hospital for Children, London, United Kingdom

7. 7West Midlands Regional Genetics Laboratory, Birmingham, United Kingdom

8. 8Alder Hey Children’s Hospital, Liverpool, United Kingdom

9. 9Southampton Children’s Hospital, Southampton, United Kingdom

10. 10Leukaemia Research Cytogenetics Group, Wolfson Childhood Cancer Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

11. 11Department of Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, United Kingdom

Abstract

Abstract T-ALL relapse usually occurs early but can occur much later, which has been suggested to represent a de novo leukemia. However, we conclusively demonstrate late relapse can evolve from a pre-leukemic subclone harbouring a non-coding mutation that evades initial chemotherapy.

Publisher

American Society of Hematology

Link

https://ashpublications.org/blood/article-pdf/143/10/933/2217090/blood_bld-2023-021906-main.pdf

Reference23 articles.

1. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children;Teachey;Blood,2020

2. Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation;Kunz;Haematologica,2015

3. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL;Tzoneva;Nat Med,2013

4. Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition;Szczepanski;J Clin Oncol,2011

5. The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia;Furness;Leukemia,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncogenic Enhancers in Leukemia;Blood Cancer Discovery;2024-08-01